Heading in the right direction...-Top line revenues up and tecord quartely revenues
-Quartely burning rate low and $ 1,9 M includig higher cost for selling and marketing plus research and development
Cash and equivalent on hand $ 28 M
-Impact from Abiomed up and signed supply agreement up to 2028
-New agreement with Premier
-FDA approval most probably at the end of the yearly financial report in November
In summary a very promising ''outlook'' and most probably taken over in less than 2 years.